discovering the true signals of disease to power life-changing medicines

90% of drug candidates fail, delaying help for people in need. We’re on a mission to change that.

Learn More

FEATURED NEWS

Sequence Bio launches genetics study of familial multiple sclerosis

September 20, 2024

NL Health Services selects Sequence Bio as an Innovation Partner

October 26, 2023

New study illustrates unique genetic landscape in Newfoundland and Labrador with links to Ireland and England

May 15, 2023

NEWFOUNDLAND AND LABRADOR

there's nowhere quite like it

Better target discovery starts with the right systems biology approach, enabled by an integrated stack of founder population multi-omics, real-world patient data, and well-characterized phenotypes.

The ability to create powered discovery cohorts for common and rare disease indications is not available everywhere, but it is in Newfoundland and Labrador.

founder effect: less biological variation enables more efficient identification of low frequency, high impact variants

complete health records: highly consistent phenotypic stratification to uncover new links between variants and disease

RESEARCH & DEVELOPMENT

better medicines, faster

Our platform is where systems biology and data-driven computation meet to identify the true signals of disease.

See how we’re working with leading pharma and biotech to shorten R&D timelines with custom discovery cohorts.

partner with sequence bio

sequence bio

leadership

We’re a committed team local and global experts united in our mission to help improve health outcomes with better medicines, faster.

We're hiring, join the team